Two Sigma Advisers’s AstraZeneca AZN Stock Holding History

Two Sigma Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-636,300	Closed	-$117M	–	228
2025 Q4	$117M	Buy	+636,300	New	+$112M	0.23%	103
2025 Q1	–	Sell	-43,050	Closed	-$5.64M	–	2391
2024 Q4	$5.64M	Buy	+43,050	New	+$6.03M	0.01%	675
2024 Q3	–	Sell	-857,050	Closed	-$134M	–	2289
2024 Q2	$134M	Sell	857,050 -64,450	-7%	-$9.7M	0.3%	74
2024 Q1	$125M	Buy	921,500 +619,650	+205%	+$82.1M	0.29%	75
2023 Q4	$40.7M	Buy	301,850 +47,350	+19%	+$6.16M	0.1%	209
2023 Q3	$34.5M	Buy	254,500 +246,400	+3,042%	+$33.7M	0.09%	201
2023 Q2	$1.16M	Sell	8,100 -5,100	-39%	-$750K	﹤0.01%	1480
2023 Q1	$1.83M	Sell	13,200 -156,450	-92%	-$21M	﹤0.01%	1318
2022 Q4	$23M	Buy	169,650 +146,150	+622%	+$18.3M	0.06%	301
2022 Q3	$2.58M	Buy	23,500 +14,600	+164%	+$1.85M	0.01%	1048
2022 Q2	$1.18M	Sell	8,900 -55,900	-86%	-$7.33M	﹤0.01%	1511
2022 Q1	$8.6M	Buy	+64,800	New	+$7.77M	0.02%	575
2021 Q3	–	Sell	-20,050	Closed	-$2.4M	–	2446
2021 Q2	$2.4M	Buy	+20,050	New	+$2.2M	0.01%	1208
2021 Q1	–	Sell	-47,400	Closed	-$4.74M	–	2551
2020 Q4	$4.74M	Sell	47,400 -383,400	-89%	-$40.6M	0.01%	844
2020 Q3	$47.2M	Buy	430,800 +34,800	+9%	+$3.87M	0.13%	155
2020 Q2	$41.9M	Buy	+396,000	New	+$40.9M	0.12%	176
2020 Q1	–	Sell	-40,250	Closed	-$4.01M	–	2453
2019 Q4	$4.01M	Sell	40,250 -21,300	-35%	-$2.01M	0.01%	932
2019 Q3	$5.49M	Sell	61,550 -85,950	-58%	-$7.45M	0.01%	731
2019 Q2	$12.2M	Buy	+147,500	New	+$11.6M	0.03%	535
2018 Q4	–	Sell	-61,500	Closed	-$4.87M	–	2348
2018 Q3	$4.87M	Buy	61,500 +56,200	+1,060%	+$4.25M	0.01%	834
2018 Q2	$372K	Sell	5,300 -73,600	-93%	-$5.3M	﹤0.01%	2030
2018 Q1	$5.52M	Sell	78,900 -103,650	-57%	-$7.18M	0.02%	811
2017 Q4	$12.7M	Sell	182,550 -3,750	-2%	-$253K	0.03%	531
2017 Q3	$12.6M	Sell	186,300 -117,700	-39%	-$7.44M	0.04%	496
2017 Q2	$20.7M	Buy	304,000 +258,750	+572%	+$16.9M	0.07%	330
2017 Q1	$2.82M	Buy	45,250 +19,600	+76%	+$1.14M	0.01%	1089
2016 Q4	$1.4M	Buy	25,650 +2,200	+9%	+$125K	0.01%	1364
2016 Q3	$1.54M	Sell	23,450 -19,240	-45%	-$1.26M	0.01%	1142
2016 Q2	$2.58M	Buy	42,690 +16,300	+62%	+$947K	0.01%	770
2016 Q1	$1.49M	Buy	26,390 +17,190	+187%	+$1.03M	0.01%	937
2015 Q4	$625K	Buy	9,200 +4,550	+98%	+$298K	﹤0.01%	1244
2015 Q3	$296K	Buy	+4,650	New	+$306K	﹤0.01%	1509
2015 Q2	–	Sell	-11,840	Closed	-$810K	–	1888
2015 Q1	$810K	Buy	+11,840	New	+$823K	0.01%	1160
2014 Q1	–	Sell	-334,800	Closed	-$19.9M	–	2253
2013 Q4	$19.9M	Sell	334,800 -426,800	-56%	-$23.2M	0.19%	109
2013 Q3	$39.5M	Buy	761,600 +641,481	+534%	+$32.2M	0.47%	37
2013 Q2	$5.68M	Buy	+120,119	New	+$6.12M	0.08%	222

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Two Sigma Advisers's AZN Position: Q1 2026 in Review

Two Sigma Advisers sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 636,300 shares — an estimated $117M sold.

Two Sigma Advisers first reported a position in AZN in Q2 2013 and held it in 36 quarters. The position peaked at $134M in Q2 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Two Sigma Advisers reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 636,300 AstraZeneca shares in Q1 2026, an estimated $117M.
Two Sigma Advisers first reported a position in AstraZeneca in Q2 2013 and held it in 36 quarters.
Two Sigma Advisers's AstraZeneca position peaked at $134M in Q2 2024.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.